ORIGINAL ARTICLE

Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition

Javier Milara,1,2,3 Rafael Navarro,4 Gustavo Juan,5 Teresa Peiró,6 Adela Serrano,1 Mercedes Ramón,4 Esteban Morcillo,3,5 Julio Cortijo1,3,5

ABSTRACT

Background Idiopathic pulmonary fibrosis (IPF) is characterised by the aberrant epithelial to mesenchymal transition (EMT) and myofibroblast accumulation. Sphingosine-1-phosphate (S1P) and sphingosine kinase 1 (SPHK1) have been implicated in lung myofibroblast transition, but their role in EMT and their expression in patients with IPF is unknown.

Methods and results S1P levels were measured in serum (n=27) and bronchoalveolar lavage (BAL; n=15) from patients with IPF and controls (n=30 for serum and n=15 for BAL studies). SPHK1 expression was measured in lung tissue from patients with IPF (n=12) and controls (n=15). Alveolar type II transformation into mesenchymal cells was studied in response to S1P (10−12−10−5 M). The median (IQR) of S1P serum levels was increased in patients with IPF (1.4 (0.4) μM versus controls (1.02 (0.26) μM; p<0.0001). BAL S1P levels were increased in patients with IPF (1.12 (0.53) μM) versus controls (0.2 (0.5); p<0.0001) and correlated with diffusion capacity of the lung for carbon monoxide, forced expiratory volume in 1 s and forced vital capacity (Spearman’s r=−0.87, −0.72 and −0.68, respectively) in patients with IPF. SPHK1 was upregulated in lung tissue from patients with IPF and correlated with α-smooth muscle actin, vimentin and collagen type I (Spearman’s r=−0.82, 0.85 and 0.72, respectively). S1P induced EMT in alveolar type II cells by interacting with S1P3 and S1P2, as well as by the activation of p-Smad3, RhoA-GTP, oxidative stress and transforming growth factor-β1 (TGF-β1) release. Furthermore, TGF-β1-induced EMT was partially conducted by the S1P/SPHK1 activation, suggesting crosstalk between TGF-β1 and the S1P/SPHK1 axis.

Conclusions S1P is elevated in patients with IPF, correlates with the lung function and mediates EMT.

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease. Owing to its poor prognosis and aggressive nature, IPF poses major challenges to clinicians. Currently, no effective treatments exist to stop ongoing fibrosis in IPF. The accumulation and persistence of myofibroblasts is believed to contribute to the development of fibrosis. α-Smooth muscle actin (α-SMA) and vimentin expression, increased proliferative capacity, and increased generation and secretion of extracellular matrix (ECM) proteins such as collagen and fibronectin are key hallmarks of myofibroblast differentiation in fibrotic disorders. It has been established that myofibroblast foci may develop as a consequence of fibroblast/myofibroblast transition, alveolar epithelial to mesenchymal transition (EMT), or recruitment of circulating fibroblastic stem cells (fibrocytes). The formation and progression of myofibroblasts occurs mainly through combinatorial signals involving transforming growth factor β1 (TGF-β1) and integrin signalling. However, it was recently shown that other growth factors such as platelet-derived growth factor and molecules such as the sphingolipid sphingosine-1-phosphate (S1P) may activate lung fibroblasts/myofibroblasts. The bioactive phospholipid S1P has been presented as a lung pro-inflammatory/pro-remodelling agent because S1P levels are increased in bronchoalveolar lavage (BAL) fluid from patients with asthma after antigen challenge and bleomycin-induced pulmonary fibrosis in animal models. Most of the S1P effects are mediated through members of the G-protein-coupled S1P receptor family, which includes ubiquitously expressed subtypes S1P1, S1P2 and S1P3. Interestingly, the main pro-fibrotic factor TGF-β1 activates and upregulates

Key messages

What is the key question?

► Is the bioactive lipid, sphingosine-1-phosphate (S1P), involved in the idiopathic pulmonary fibrosis (IPF) process?

What is the bottom line?

► S1P and sphingosine kinase 1 (SPHK1) are upregulated in serum, bronchoalveolar lavage and lung tissue of patients with IPF, correlate with lung function and mediate epithelial to mesenchymal transition.

Why read on?

► This is the first report that relates S1P and SPHK1 with the IPF process and with the epithelial to mesenchymal transition as an underlying cellular process. The data presented in this study could be of potential value in future antifibrotic therapeutic interventions focused on the S1P system.
sphingosine kinase 1 (SphK1), the enzyme that catalyses phosphorylation of sphingosine to produce S1P. Thus, SphK1 establishes a link between TGF-β1 and S1P to promote common pro-fibrotic actions by means of S1P receptor transactivation. Despite in vitro evidence of S1P and SphK1 in lung fibroblast activation, there is no evidence of either the effect of S1P on the EMT process or the presence and distribution of S1P and SphK1 in patients with IPF. Therefore, we hypothesised that S1P and SphK1 could be over-expressed in patients with IPF and that S1P could mediate EMT in human alveolar epithelial cells, which in turn may contribute to lung fibrosis formation and progression.

The aim of this study was to investigate S1P and SphK1 expression in serum, BAL and lung tissue from controls and patients with IPF and to analyse the effect of S1P on alveolar EMT as a new myofibroblast inducer.

**MATERIALS AND METHODS**

**Patients with IPF**
A total of 27 patients with IPF were included in the study. IPF was diagnosed according to the American Thoracic Society/European Respiratory Society (ATS/ERS) consensus criteria.

Fibrotic lung samples were obtained by open lung biopsy. Serum samples were obtained from peripheral blood, and alveolar macrophages were obtained and isolated from BAL as described below.

**Controls**
Lung tissue samples were obtained from patients undergoing thoracic surgery for removal of a primary lung tumour. Normal lung was obtained from a non-involved segment, remote from the solitary lesion. Serum samples were obtained from healthy subjects without any medical disease. Control BAL and control alveolar macrophages were obtained from patients who were undergoing bronchoscopy as a diagnostic approach to haemoptysis, which in all cases showed no macroscopic lesions; further, no radiological anomalies were shown on CT. To investigate whether airways were colonised with bacteria, bronchial secretions were obtained using a protected specimen brush. These were found to be culture negative in all cases. The protocol was approved by the local research and independent ethics committee of the University General Hospital of Valencia. Informed written consent was obtained from each participant.

**Cell culture and stimulation**
Alveolar macrophages were isolated from BAL fluid by means of adherence properties on a culture cell plate. Human alveolar type II cells (ATII) were isolated from human lung tissue as described previously, with modifications (see online supplement). The A549 cells were purchased from American Type Culture Collection (Rockville, Maryland, USA). Stimulation conditions and inhibitors are defined in the online supplement.

**Proliferation assay**
Cell proliferation was measured by colorimetric immunoassay based on BrdU incorporation during DNA synthesis using a cell proliferation ELISA BrdU kit (Roche, Mannheim, Germany) according to the manufacturer’s protocol, as previously outlined.

**Detection of RhoA-GTP, S1P, total soluble collagen, and supernatant TGF-β1**
Analysis of intracellular RhoA-GTP, S1P, soluble collagen and TGF-β1 was performed using an RhoA-GTP activity assay kit (G-LISA; Cytoskeleton, Denver, Colorado, USA), S1P competitive ELISA kit (Echelon Biosciences Inc., Salt Lake City, Utah, USA), Sircol assay kit (Biozol, Berlin, Germany) and Quantikine Human TGF-β1 Immunoassay (catalogue no. 891124; R&D Systems). See online supplement for further details.

**Real-time PCR**
Real-time PCR was performed as previously described. Relative quantification of different transcripts was determined by the 2−ΔΔCt method, using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control and with normalisation to the control group. See online supplement for further details.

**Protein array**
Protein expression in lung tissue samples from controls and patients with IPF was analysed with Zeptosens (Division of Bayer (Schweiz), Switzerland) protein array technology as previously outlined. See online supplement for further details.

**Western blot analysis**
Protein expression in A549 cells was analysed by western blot as previously described. Primary antibodies against SphK1, TGF-β1, α-SMA, vimentin, E-cadherin and p-Smad were used. See online supplement for further details.

**Immunohistochemistry**
SphK1 immunohistochemical analysis of human pulmonary tissue was performed using rabbit anti-human SphK1 antibody (1:100; Sigma, Madrid, Spain). Details are described in the online supplement.

**DCFDA fluorescence measurement of reactive oxygen species**
Intracellular reactive oxygen species (ROS) levels (H2O2 and superoxide anion) were measured in A549 cells by means of dichlorofluorescein diacetate (DCFDA) dye as previously outlined. See online supplement for further details.

**Statistics**
Statistical analysis of the results was carried out by parametric or non-parametric analysis as appropriate. Significance was accepted when p<0.05. Details are described in the online supplement.

**RESULTS**

**S1P levels and SphK1 expression are increased in patients with IPF**
Controls and patients with IPF were prospectively recruited from the Respiratory Unit, University General Hospital Consortium, Valencia, Spain between 2008 and 2010 at the initial diagnostic work-up. Clinical data of patients are shown in table 1. Serum and BAL levels of S1P were significantly higher in patients with IPF than in controls (p<0.0001) (figure 1A,B). The SphK1 mRNA transcript level was increased in alveolar macrophages of patients with IPF compared with controls (p=0.004) (figure 1C). No correlation was found between the serum S1P levels in patients with IPF and the clinical features or radiological findings. In contrast, BAL S1P levels in patients with IPF were inversely correlated with diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 s (FEV1), and diffusion capacity for carbon monoxide (DLCO) (figure 1D).

---

**Thorax: first published as 10.1136/thoraxjnl-2011-200026 on 21 November 2011. Downloaded from http://thorax.bmj.com/ on April 29, 2022 by guest. Protected by copyright.
Table 1  Clinical features of patients

<table>
<thead>
<tr>
<th></th>
<th>Controls included in lung tissue studies (n = 15)</th>
<th>Controls included in serum studies (n = 30)</th>
<th>Controls included in BAL-AM studies (n = 15)</th>
<th>Patients with IPF (n = 27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66 (53–80)</td>
<td>67 (42–81)</td>
<td>66 (47–79)</td>
<td>68 (48–86)</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>10/5</td>
<td>18/12</td>
<td>10/5</td>
<td>16/11</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoked/smokers</td>
<td>4/11</td>
<td>13/17</td>
<td>5/10</td>
<td>18/9</td>
</tr>
<tr>
<td>Pack-year</td>
<td>28 (0–30)</td>
<td>24 (0–30)</td>
<td>27.5 (0–35)</td>
<td>30 (0–40)</td>
</tr>
<tr>
<td>FEV1, % pred</td>
<td>95 (90–110)</td>
<td>96 (90–115)</td>
<td>98 (92–110)</td>
<td>72 (50–120)</td>
</tr>
<tr>
<td>FVC, % pred</td>
<td>96 (90–110)</td>
<td>98 (90–115)</td>
<td>99 (90–115)</td>
<td>74 (43–120)</td>
</tr>
<tr>
<td>TLC, % pred</td>
<td>95 (90–105)</td>
<td>96 (87–110)</td>
<td>94 (87–105)</td>
<td>66 (43–90)</td>
</tr>
<tr>
<td>DLco, % pred</td>
<td>94 (80–107)</td>
<td>97 (80–107)</td>
<td>94 (80–107)</td>
<td>40.5 (20–63)</td>
</tr>
<tr>
<td>% Ground Glass</td>
<td>0</td>
<td>ND</td>
<td>0</td>
<td>10 (0–50)</td>
</tr>
<tr>
<td>% Honeycombing</td>
<td>0</td>
<td>ND</td>
<td>0</td>
<td>25 (0–60)</td>
</tr>
<tr>
<td>BAL, %+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrophages</td>
<td>90.2 (72–100)</td>
<td>ND</td>
<td>96 (75–100)</td>
<td>79 (48–90)</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>7 (2–10)</td>
<td>ND</td>
<td>5 (2–9)</td>
<td>6 (2–19)</td>
</tr>
<tr>
<td>CD4/CD8</td>
<td>1.3 (0.6–2)</td>
<td>ND</td>
<td>1.2 (0.5–2)</td>
<td>0.9 (0.1–2)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>1.2 (0.2–4)</td>
<td>ND</td>
<td>1.1 (0.2–4)</td>
<td>8 (1–30)</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>0.7 (0–1)</td>
<td>ND</td>
<td>0.6 (0–1)</td>
<td>3 (0–8)</td>
</tr>
<tr>
<td>PaO2, mm Hg</td>
<td>94 (84–100)</td>
<td>96 (85–100)</td>
<td>95 (85–100)</td>
<td>60 (40–85)</td>
</tr>
<tr>
<td>Steroid (yes/no)</td>
<td>0/15</td>
<td>0/30</td>
<td>0/15</td>
<td>12/15</td>
</tr>
<tr>
<td>Azathioprine (yes/no)</td>
<td>0/15</td>
<td>0/30</td>
<td>0/15</td>
<td>6/21</td>
</tr>
</tbody>
</table>

Steroid/azathioprine is referring to patients who received this treatment at the moment of pulmonary biopsy.

Data are the median (range), AM, alveolar macrophage; BAL, bronchoalveolar lavage; DLco, diffusion capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; ND, not determined; pack-year smoking 20 cigarettes/day; PaO2, oxygen tension in arterial blood; TLC, total lung capacity; % Ground Glass, % of pulmonary parenchyma with Ground Glass in CT image; % Honeycombing, % of pulmonary parenchyma with honeycombing in CT image; % pred, % predicted.

![Table 1 Clinical features of patients](image)

**S1P induces alveolar EMT**

The ATII epithelial cell line A549 cultured in the absence of S1P maintained classic cobblestone epithelial morphology as assessed by phase contrast light microscopy (figure 3A). A concentration of $10^{-7}$ M S1P (72 h) began to induce morphological changes in A549 cells, characterised by a more fibroblast-like morphology with reduced cell–cell contact (figure 3A). In addition, mRNA transcripts of the epithelial cell markers ZO-1 and E-cadherin were significantly downregulated, and mRNA transcripts of the mesenchymal phenotype markers $\alpha$-SMA, vimentin and col type I were upregulated in a dose-dependent manner after S1P exposure, which confirmed EMT (figure 3B). Protein analysis further confirmed these results for $\alpha$-SMA, vimentin and E-cadherin (figure 3C) as well as for total soluble collagen (figure 3D). Primary human ATII cells stimulated with $10^{-6}$ M S1P for 72 h showed similar changes (figure 3E). The observed changes in cell phenotype were accompanied by the arrest of cell growth after 72 h of S1P stimulation (figure 3F).

![Figure 1 Sphingosine-1-phosphate (S1P) and sphingosine kinase 1 (SPHK1) are increased in patients with idiopathic pulmonary fibrosis (IPF)](image)

Each sample. p Values for comparison by Mann Whitney test are shown.
S1P-induced EMT is partially mediated by RhoA-GTP, Smad3, intracellular ROS and autocrine TGF-β1 action

The Rho kinase inhibitor Y27632, Smad3 inhibitor SIS3 and antioxidant N-acetyl-L-cysteine (NAC) suppressed the S1P-induced phenotypic changes in A549 cells (figure 4A) and partially suppressed the increase in α-SMA, vimentin and collagen as well as the decrease in E-cadherin protein expression (figure 4B,C). It was recently suggested that S1P shares common intracellular pathways with TGF-β1 and that S1P may transactivate TGF-β1 receptor.13 In the present work, TGF-β1 promoted EMT in a manner similar to that of S1P (figure 4AeC). Furthermore, anti-TGF-β1 antibody inhibited S1P-induced EMT, suggesting an autocrine role for TGF-β1 (figure 4B,C). Specifically antagonists for S1P1, S1P2 and S1P3 were used to elucidate the S1P receptor subtypes required for the S1P-induced EMT process. The S1P2 inhibitor JTE013 and the S1P3 inhibitor CAY10444 attenuated S1P-induced α-SMA, vimentin and collagen upregulation and E-cadherin downregulation, whereas the S1P1 inhibitor W146 had no effect (figure 5A,B).

S1P upregulates Smad3 phosphorylation, RhoA-GTP activation and intracellular ROS production

Smad3, RhoA-GTP and intracellular ROS have been implicated in the EMT process.14 We observed that after 30 min of exposure, S1P increased Smad3 phosphorylation, and only the S1P3 antagonist CAY10444 alleviated Smad3 phosphorylation (figure 6A). In other experiments, A549 cells were stimulated with S1P for 72 h, and phospho-Smad3 was quantified. The S1P-induced Smad3 phosphorylation after 72 h was suppressed by CAY10444 and JTE013, but not by W146 (figure 6B). Furthermore, anti-TGF-β1 antibody partially suppressed S1P-induced Smad3 phosphorylation, suggesting an autocrine role for TGF-β1 (figure 6B). In a similar fashion, S1P activated RhoA-GTP following 30 min and 72 h of S1P exposure, and this was suppressed by CAY10444 and JTE013, but not by W146 (figure 6C,D).

S1P elicited an increase in intracellular ROS in a similar way as the positive control H2O2, with the highest levels after 10 min of stimulation. Pre-treatment with CAY10444 or JTE013 attenuated the S1P-induced ROS generation; pre-treatment with W146 was without effect (figure 6C).

S1P increases TGF-β1 expression and secretion

It was recently shown that intracellular ROS may induce TGF-β1 secretion.15 Because S1P promotes intracellular ROS formation, we explored whether S1P could also increase TGF-β1 expression and secretion. After 72 h of exposure, S1P increased TGF-β1 expression and secretion approximately twofold (figure 7A–C). JTE013 and CAY10444 attenuated...
S1P-induced TGF-β1 expression and secretion, whereas W146 had no effect (figure 7A–C). When intracellular ROS was removed by NAC, TGF-β1 remained at levels similar to control levels, suggesting a direct role of ROS in S1P-induced TGF-β1 expression. Moreover, anti-TGF-β1 antibody totally suppressed S1P-induced TGF-β1 expression, which confirms the removal capacity of this antibody.

TGF-β1-induced EMT is partially mediated by the SPHK1/S1P2–3 axis

TGF-β1 dose-dependently upregulated SPHK1 protein expression in A549 cells (figure 8A). However, we did not detect S1P in cell supernatants following TGF-β1 stimulation, probably because S1P is rapidly degraded by extracellular lipid phosphate phosphatases (data not shown).16
In other experiments, TGF-β1 (5 ng/ml, 72 h) induced EMT in A549 cells, as evidenced by increased α-SMA, vimentin and collagen type I mesenchymal markers and decreased E-cadherin and ZO-1 epithelial markers (figure 8B,C). Either JTE013 or CAY10444 as well as the SPHK inhibitor DMS attenuated TGF-β1-induced EMT. Furthermore, Y27632, SIS3 and NAC partially suppressed TGF-β1-induced EMT, confirming the participation of Rho kinase, Smad3 and ROS as previously mentioned.

**DISCUSSION**

The main and novel results of the present study are that serum S1P levels were upregulated in patients with IPF; S1P levels in BAL fluid were increased in patients with IPF and were inversely correlated with DLco, FEV1 and FVC; SPHK1 mRNA expression was upregulated in alveolar macrophages and lung tissue from patients with IPF and was correlated with the fibroblast markers α-SMA, vimentin and collagen type I; and S1P induced alveolar EMT in ATII and A549 cells through the activation of S1P2 and S1P3 with downstream signalling involving phospho-Smad3, RhoA-GTP and intracellular ROS, and by crosstalk between S1P/SPHK1 and TGF-β1 pathways. These new findings suggest that S1P may play a role in IPF, potentially by modulating the differentiation of alveolar epithelial cells to the mesenchymal phenotype as well as by the previously reported differentiation of fibroblasts into myofibroblasts.

In the present work, serum S1P levels in the control group were 1 μM, which is consistent with previous data in normal subjects. In contrast, patients with IPF showed significantly higher serum S1P levels that reached 1.4 μM. The significance of these findings is currently unknown; however, based on previous results in animal models, we hypothesise that chronically elevated S1P levels disrupt endothelial barrier integrity and thereby contribute to lung fibrosis, as suggested by the exacerbated vascular leakage, fibrosis and mortality observed in mice exposed to the S1P analogue FTY720 after lung injury.
A recent animal model of bleomycin-induced pulmonary fibrosis revealed that acid sphingomyelinase (ASMase) and acid ceramidase (AC) activities are increased in the lungs of fibrotic mice, and that ASMase knockout attenuated lung fibrosis. ASMase is a lysosomal enzyme responsible for the hydrolysis of sphingomyelin, which results in the production of ceramide and sphingosine-1-phosphate (S1P)-induced epithelial to mesenchymal transition (EMT) was mediated via S1P₂ and S1P₃. A549 cells were incubated with the S1P₁ inhibitor W146 (1 μM), S1P₂ inhibitor JTE013 (1 μM) or S1P₃ inhibitor CAY10444 (10 μM) for 30 min before S1P (1 μM) stimulation for 72 h. (A) Representative images of three western blots with respective densitometry analyses are shown for the mesenchymal markers α-smooth muscle actin (α-SMA) and vimentin and the epithelial marker E-cadherin. Results were corrected to β-actin as an internal control and normalised to the non-treated vehicle group. (B) Total soluble collagen in cell cultures was measured by the Sircol assay. Results are the means (SE) of three independent experiments. Post hoc Bonferroni tests: exact p values down to 0.05 are indicated in the graph (related to the indicated values or to solvent controls if placed on top of a bar); *p<0.05; **p<0.01 related to solvent controls; †p<0.05; ††p<0.01 related to S1P-stimulated cell values as indicated.

Figure 5

Figure 6

Sphingosine-1-phosphate (S1P) increases Smad3 phosphorylation, RhoA-GTP activation, and intracellular reactive oxygen species (ROS) generation. A549 cells were incubated with the S1P₁ inhibitor W146 (1 μM), S1P₂ inhibitor JTE013 (1 μM), S1P₃ inhibitor CAY10444 (10 μM) or anti-transforming growth factor-β1 (TGF-β1) antibody (4 μg/ml) and its negative control (non-immune IgG) for 30 min before S1P (1 μM) stimulation for 30 min or 72 h. (A) Representative images of three western blots with respective densitometry analyses are shown for p-Smad3 and total Smad3 after 30 min of S1P exposure. (B) Representative images of three western blots with respective densitometry analyses are shown for p-Smad3 and total Smad3 after 72 h of S1P exposure. Results were corrected to total Smad3 and normalised to the non-treated vehicle group. Cell lysates were obtained after (C) 30 min or (D) 72 h of S1P exposure, and an ELISA-based RhoA-GTP activity assay was performed. (E, F, G and H) Intracellular ROS were determined by means of dichlorofluorescin (DCF) fluorescence intensity after S1P (1 μM) stimulation in the presence or absence of (F) W146 (1 μM), (G) JTE013 (1 μM) or (H) CAY10444 (10 μM). (E) H₂O₂ (400 μM) was used as a positive intracellular ROS inducer. Results are the means (SE) of three independent experiments. Post hoc Bonferroni tests: exact p values down to 0.05 are indicated in the graph (related to the indicated values or to solvent controls if placed on top of a bar); *p<0.05 related to solvent controls; †p<0.05 related to S1P-stimulated cell values as indicated.
results are the means (SE) of three independent experiments. Post hoc Bonferroni tests: exact p values down to 0.05 are indicated.

S1P-stimulated cell values as indicated.

the S1P1 inhibitor W146 (1 μM), S1P2 inhibitor JTE013 (1 μM), S1P3 inhibitor CAY10444 (10 μM), antioxidant N-acetyl-L-cysteine (1 mM; NAC), or anti-TGF-β1 antibody (4 μg/ml) and its negative control (non-immune IgG) for 30 min before S1P (1 μM) stimulation for 72 h. (A) S1P increased TGF-β1 secretion as measured by ELISA. (B) S1P increased TGF-β1 mRNA and (C) protein expression as measured by real-time PCR and western blot analysis, respectively. (C) Representative images of three western blots with respective densitometry analyses are shown for TGF-β1 and β-actin as an internal control. Results are the means (SE) of three independent experiments. Post hoc Bonferroni tests: exact p values down to 0.05 are indicated in the graph (related to the indicated values or to solvent controls if placed on top of a bar); *p<0.05 related to solvent controls; †p<0.05 related to S1P-stimulated cell values as indicated.

Finally S1P. Furthermore, AC degrades ceramide to sphingosine, which is converted into S1P by means of SPHK. Bleomycin-induced ASMase and AC activation increased S1P levels in fibroblast cell cultures, which may explain the downstream effects of ASMase activation in bleomycin-induced mouse lung fibrosis. In support of these findings, it was recently shown that genetic deletion of SPHK1 protected mice from bleomycin-induced lung fibrosis and mortality. In the present study, the increase in SPHK1 expression in lung tissues from patients with IPF was correlated with α-SMA, vimentin and col type I expression. These results are in agreement with previous data showing upregulation of SPHK1, α-SMA, fibronectin and collagen in a mouse model of bleomycin-induced lung fibrosis. Interestingly, in SpHK1−/− mice, the bleomycin-induced enhanced expression of α-SMA, fibronectin and collagen was attenuated, suggesting a potential role for SPHK1 in lung fibrosis. Along this line, it has been shown that SPHK1 and α-SMA are co-localised within mouse lung fibroblasts, confirming a common pattern of expression during lung fibrosis development. In this work, we observed increased SPHK1 expression located in fibroblasts and on the hyperplastic alveolar cells of patients with IPF, which represents a previously unappreciated finding and suggests a potential role for S1P in ATII and fibroblast activation and transformation. Besides the results observed in this study, some important limitations need to be discussed (see online supplementary data).

Following our evolving hypothesis, which suggests that IPF is a consequence of impaired wound healing involving the epithelial/fibroblast pathway, many candidate growth factor genes as well as other molecular mediators implicated in this extensive process have been evaluated. For example, TGF-β1 is a well characterised in vivo and in vitro growth factor mediating fibroblast and alveolar epithelial transformation into myofibroblasts. Myofibroblasts localise to fibrotic foci and other sites of active fibrosis and are the primary cell type responsible for the synthesis and deposition of ECM and the resultant structural remodelling that leads to the loss of alveolar function. SPHK1 inhibition suppresses the TGF-β1-induced fibroblast to myofibroblast transition, and previous reports have proposed a crosstalk between the S1P/SPHK and TGF-β1 pathways. Furthermore, TGF-β1 may trans-activate fibroblast S1P2 and S1P3, but not S1P1, to promote myofibroblast differentiation. Based on this background, we hypothesise that S1P may also promote alveolar EMT, which is one of the main processes of myofibroblast formation in IPF. In a recent study, S1P induced EMT in retinal pigmented cells. However, no data are available concerning alveolar epithelial cells. We observed that S1P induces alveolar EMT as assessed by increases in the myofibroblast markers α-SMA, vimentin and col type I and by the down-regulation of the epithelial markers E-cadherin and ZO-1. The change in the ATII epithelial phenotype was accompanied by an arrest of cell growth. Although we previously reported that S1P promotes proliferation in A549 cells after 24 h, chronic stimulation during 72 h inhibited A549 cell growth. It is known that while cells are undergoing a differentiation process, they are not proliferative. Thus, for example, TGF-β1 inhibits A549 proliferation, and chronic S1P stimulation inhibits human keratinocyte proliferation.

S1P-induced EMT was mediated by the activation of S1P2 and S1P3, which is in accordance with previous results in lung fibroblasts. However, S1P2 and S1P3 played a different role in the S1P-induced EMT process. S1P1, through its interaction with S1P3, directly increased the phosphorylation of Smad3. In contrast, the S1P2 antagonist suppressed phospho-Smad3 expression following 72 h of S1P exposure, in a manner similar to that of the anti-TGF-β1 antibody. This observation may be explained because the S1P2 antagonist reduced S1P-induced TGF-β1 secretion after 72 h and therefore could indirectly inhibit Smad3 phosphorylation induced by TGF-β1, suggesting an autocrine role for TGF-β1 in the S1P-induced EMT process. This hypothesis was confirmed when the anti-TGF-β1 antibody attenuated the S1P-induced EMT process.

In addition, S1P-induced EMT was mediated by an increase in intracellular ROS and RhoA-GTP. Oxidative stress has been shown to promote TGF-β1 release. Thus, S1P-induced ROS could be responsible for TGF-β1 release and thereby for the EMT.
TGF-β1

0 0.5 2 10 ng/ml

SHPK1 (42 kD)

β-actin

A

Vehicle
TGFB-1
TGFB-1 + W146
TGFB-1 + JTE013
TGFB-1 + CAY10444
TGFB-1 + Y27632
TGFB-1 + SIS3
TGFB-1 + NAC
TGFB-1 + DMS

B

Vehicle
TGFB-1
TGFB-1 + W146
TGFB-1 + JTE013
TGFB-1 + CAY10444
TGFB-1 + Y27632
TGFB-1 + SIS3
TGFB-1 + NAC
TGFB-1 + DMS

C

Vehicle
TGFB-1
TGFB-1 + W146
TGFB-1 + JTE013
TGFB-1 + CAY10444
TGFB-1 + Y27632
TGFB-1 + SIS3
TGFB-1 + NAC
TGFB-1 + DMS

Figure 8  Transforming growth factor-β1 (TGFB-1)-induced alveolar epithelial to mesenchymal transition (EMT) is partially mediated by the sphingosine-1-phosphate (S1P)/sphingosine kinase 1 (SHPK1) axis. (A) A549 cells were stimulated with TGFB-1 at different concentrations for 72 h, and SHPK1 expression was measured by western blot analysis. Representative images of three western blots with their respective densitometry analyses are shown for SHPK1 and β-actin as an internal control. (B) and (C) A549 cells were incubated with the Rho-kinase inhibitor Y27632 (10 μM), Smad3 inhibitor SIS3 (10 μM), antioxidant N-acetyl-l-cysteine (NAC; 1 mM), S1P1 inhibitor W146 (1 μM), S1P2 inhibitor JTE013 (1 μM), S1P3 inhibitor CAY10444 (10 μM) or SPHK inhibitor N,N-dimethylyosphingosine (DMS) for 30 min before TGFB-1 (5 ng/ml; 72 h) stimulation. Following the incubation periods, mRNA was extracted, and the mesenchymal markers α-smooth muscle actin (α-SMA), vimentin and collagen (col) type I and epithelial markers E-cadherin and ZO-1 were quantified by real-time PCR. Results are the means (SE) of three independent experiments. Post hoc Bonferroni tests: exact p values down to 0.05 are indicated in the graph (related to the indicated values or to solvent controls if placed on top of a bar); *p<0.05; **p<0.01; ***p<0.001 related to solvent controls; †p<0.05; ††p<0.01 related to TGFB-1-stimulated cell values as indicated.

In summary, this is the first report that identifies S1P as a potential marker of human IPF as well as an inducer of alveolar EMT, confirming the crosstalk between S1P and TGF-β1. To further elucidate potential crosstalk mechanisms, we demonstrated that TGF-β1 exposure upregulated SHPK1, as previously reported in fibroblasts. Furthermore, TGF-β1-induced EMT in A549 cells was inhibited by an antagonist of SHPK as well as by antagonists of S1P1 and S1P3, providing more evidence for crosstalk between S1P/SPHK and TGF-β1. It is interesting to note that all of these intracellular pathways are related to IFP because ROS, Smad3 and β-catenin are elevated in fibrosis and in the S1P-induced fibroblast-to-myofibroblast transition. 4 5

In summary, this is the first report that identifies S1P as a potential marker of human IPF as well as an inducer of alveolar EMT, which is known to participate in the progression of IPF. The effect of S1P on EMT could be explained by a crosstalk mechanism between the S1P/SPHK1 and TGF-β1 pathways. The data presented in this study suggest that S1P may be involved in the disease process and therefore future anti-fibrotic therapeutic interventions focused on the S1P system could be of potential value.

Acknowledgements We are grateful for the valuable help of Professor M Guirao and Professor Martorell of the Thoracic Surgery and Pathology Departments of the Valencia University General Hospital for providing lung tissue.

Funding This work was supported by grants SAF2008-03113 (JC), SAF2009-08913 (EJM), CIBERES (CB06/06/0027) from the Ministry of Science and Innovation and the Health Institute 'Carlos III' of the Spanish government, and research grants (Prometeo/2008/045 and Emerging Groups GE-028/10) from the regional government (Generalitat Valenciana) and the Valencia Society of Pneumology.

Competing interests None.

Patient consent Obtained.

Ethics approval This study has been approved by the ethics committee of the University General Hospital of Valencia, Spain.

Contributors Javier Milana: contributed to immunohistochemistry analysis and drafting the original manuscript, and contributed to and approved the final manuscript. Rafa Navarro: contributed to supervising clinical characterization, coordinating the bronchoalveolar lavage sampling and analysis, and contributed to and approved the final manuscript. Gustavo Juán: contributed to supervising clinical characterization, coordinating the bronchoalveolar lavage sampling and analysis, and contributed to and approved the final manuscript. Teresa Peiró: contributed to undertaking laboratory characterization of patients, protein array and ELISAs, and contributed to and approved the final manuscript. Mercedes Ramon: contributed to undertaking laboratory characterization of patients, western blot real-time PCR and ELISAs, and contributed to and approved the final manuscript. Esteban Mercilo: contributed to conception of the project design and contributed to and approved the final manuscript.

Provenance and peer review Not commissioned; externally peer-reviewed.
Environmental micro-organisms and childhood asthma: the more the merrier?

Epidemiological studies have shown that children who grow up on traditional farms are protected from atopic conditions, including asthma. However, how this protection arises is not clearly understood. It has been postulated that immunological responses to an increased microbial exposure in early childhood is important. This study investigates, specifically, whether it is the variety of microbial exposure that is protective.

Two cross-sectional studies are described (PARSIFAL n = 489 and GABRIELA n = 444) in which the prevalence of asthma and atopy in children who live on farms are compared with a control group. Samples of dust were collected from children’s bedrooms and analysed for bacteria and fungi. Results showed that the farm-dwelling children were exposed to a greater diversity of micro-organisms, even in an indoor environment. Furthermore, the prevalence of asthma was inversely related to the greater diversity of microbial exposure, independent of whether the children lived on a farm or not. Neither study showed a significant inverse correlation with atopy.

The finding that microbial diversity protects children against asthma is an important but potentially misleading one. The study discusses the dangers of accepting this hypothesis, as the number of receptors that trigger the innate immune system are limited and easily saturated. The study was only able to identify families of species of microbes, but it has taken the first step towards finding individual micro-organisms that may contribute to the protection that farms confer to their inhabitants and therefore a potential live vaccine against asthma.


K Srikanthan

Correspondence to K Srikanthan, Core Medical Trainee, Department of Transplantation, Harefield Hospital, Harefield UB9 6JH, UK; karthinskiranthan@doctors.org.uk

Published Online First 23 May 2011

Thorax 2012;67:156. doi:10.1136/thoraxjnl-2011-200404
ONLINE SUPPLEMENT

TITLE
Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition.

AUTHORS
Javier Milara,1,2,3 Rafael Navarro,4 Gustavo Juan,5 Teresa Peiró,6 Adela Serrano,1 Mercedes Ramón,4 Esteban Morcillo,3,5 Julio Cortijo.1,3,5

AFFILIATIONS:
1 Research foundation, University General Hospital Consortium, Valencia, Spain
2 Department of Biotechnology, Universidad Politécnica de Valencia
3 CIBERES, Health Institute Carlos III, Valencia, Spain
4 Respiratory Unit, University General Hospital Consortium, Valencia, Spain
5 Department of Medicine, Faculty of Medicine, University of Valencia, Spain
6 Department of Pharmacology, Faculty of Medicine, University of Valencia, Spain

MATERIAL AND METHODS

Cell culture and stimulation
Alveolar macrophages were isolated from BAL fluid by means of adherence properties on a culture cell plate. Macrophage cell purity was 99.2 ± 4.9% as assessed by May-Grunwald staining of cytospin preparations.

Human alveolar type II cells (ATII) were isolated from human lung tissue as described previously, with modifications.1 The protocol for purification was as described previously with modifications.2 Briefly, to isolate alveolar type II cells, lung
parenchyma tissue was cut in approximately 1 mm thick sections and lavaged with saline. The lung sections were digested with 0.25% trypsin (T8003; Sigma, St. Louis, MO) dissolved in saline (100 ml) and suspended in 0.9% NaCl at 37°C for 30 minutes. After digestion, the lung sections were treated with DNase dissolved in saline (7,500 U/100 ml), and filtered through nylon meshes ranging in pore size from 150 to 30 mm. The resulting cell suspension was centrifuged (250 x g, 20 min at 10°C) through a sterile Percoll gradient and the alveolar type II cell–rich band was removed. A second DNase treatment (2,000 U/100 ml) was administered and the cells were recovered as a pellet by centrifugation at 250 x g for 20 minutes. These cells were resuspended in 5 ml of DCCM-1 (Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with a 2% (wt/vol) L-glutamine and subjected to differential attachment on a plastic Petri dish. No adherent alveolar type II cells were collected after 2 hours and cells were counted to establish the final yield of freshly purified cells. Alveolar type II cell viability was assessed with trypan blue (Sigma), showing greater than 95% viability. Cell purity was routinely assessed by epithelial cell morphology and immunofluorescence analysis with pan-cytokeratin and pro-surfactant protein C (both positive) as well as α-SMA and CD45 (both negative) of cytocentrifuge preparations of ATII cells. ATII cells used throughout this study demonstrated 95% ± 3% purity. Finally, ATII cells were suspended in DMEM plus 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin and cultured for 24 hours to allow attachment. Phenotypic characterization was done after this time period. After media change, cells were cultured for a maximum of 3 days in a humidified atmosphere of 5% CO₂ at 37°C.

The A549 cells were purchased from American Type Culture Collection (Rockville, MD, USA) and were cultured in supplemented Roswell Park Memorial Institute (RPMI) 1640 medium at 37°C in a humidified atmosphere of 5% CO₂ in air, as outlined.³ Cells
at 60–70% confluence were serum-deprived by incubation for 12–18 h in RPMI 1640 medium containing 0.1% (v/v) foetal bovine serum prior to stimulation with S1P or other agents. The human type II alveolar cell line A549 has been broadly used as a model of EMT because it retains features and metabolic properties characteristic of type II cells.⁴⁻⁶ Thus, A549 cells were considered to be an appropriate model in which to study the effect of S1P on EMT. Different drug modulators were added 30 min before S1P. Stimulators and pharmacological modulators were replaced each 24 h. S1P (10⁻⁸–10⁻⁵ M), TGF-β1 (5 ng/ml), Rho kinase inhibitor Y27632 (10 µM), Smad3 inhibitor SIS3 (10 µM), and the antioxidant N-acetyl-cysteine (1 mM; NAC) were purchased from Sigma Chemical Co. (UK), and the SPHK1 inhibitor N,N-dimethylsphingosine (5 µM, DMS) was purchased from Cayman Chemical (Ann Arbor, MI, USA). W146 (1 µM; Avanti Polar Lipids, Inc., USA), JTE013 (1 µM; Cayman Chemical, USA), and CAY10444 (10 µM; Cayman Chemical) were used to selectively inhibit S1P₁, S1P₂, and S1P₃, respectively, as previously outlined.⁷⁻⁹ Monoclonal anti-human TGF-β1 antibody (4 µg/mL; anti-TGF-β1; catalogue no. AB-246-NA; R&D Systems, Madrid, Spain) was added 30 min before a stimulus to block the active form of TGF-β1 in the culture supernatant, as previously described.¹⁰

Detection of RhoA-GTP, S1P, total soluble collagen, and supernatant TGF-β1

A commercially available enzyme-linked immunosorbent assay (ELISA)-based RhoA-GTP activity assay (G-LISA; Cytoskeleton, Denver, CO, USA) was used to measure the relative RhoA-GTP activity of serum-starved A549 cells after experimental treatments, as previously outlined.¹¹ S1P levels in human serum and BAL fluid were analysed using an S1P competitive ELISA kit (Echelon Biosciences Inc., Salt Lake City, UT, USA) according to the manufacturer’s instructions. Total soluble collagen was measured in
A549 culture supernatants by the Sircol assay (Biocolor, Belfast, Ireland), according to the manufacturer’s instructions. Quantitative ELISAs for TGF-β1 were performed with supernatants of subconfluent A549 cells on a six-well plate following 72 h of S1P (1 µM) stimulation, using a Quantikine Human TGF-β1 Immunoassay (catalogue no. 891124; R&D Systems) according to the manufacturer’s instructions.

Real Time RT-PCR

Total RNA was isolated from cultured human bronchial fibroblasts by using TriPure® Isolation Reagent (Roche, Indianapolis, USA). Integrity of the extracted RNA was confirmed with Bioanalizer (Agilent, Palo Alto, CA, USA). The reverse transcription was performed in 300 ng of total RNA with the TaqMan reverse transcription reagents kit (Applied Biosystems, Perkin-Elmer Corporation, CA, USA). cDNA was amplified using assays-on-demand specific primers pre-designed by Applied Biosystems for SPHK1 (cat. n°: Hs00184211_m1), α-SMA (cat. n°: Hs00909449_m1) vimentin (cat. n°: Hs00185584_m1) col type I (cat. n°: Hs01028970_m1), E-cadherin (cat. n°: Hs01023894_m1), ZO-1 (cat. n°: Hs01551876_m1), TGF-β1 (cat. n°: Hs00171257_m1) and GAPDH (cat. n°: 4352339E) as a housekeeping. Relative quantification of these different transcripts was determined with the 2−ΔΔCt method using glyceraldehyde phosphate dehydrogenase (GAPDH) as endogenous control (Applied Biosystems; 4352339E) and normalised to control group.

Protein array

Lung tissues were first homogenized with ultraturrax T-25 (ICT SL, Spain), lysated with CeLyA Lysis Buffer CLB1 (Zeptosens), incubated during 30 minutes at room
temperature and centrifuged (5 min at 15,000xg) in order to remove debris. The supernatants were collected, frozen in liquid nitrogen and stored at -80°C.

Protein concentration was determined using a Bradford-Coomassie Plus Assay Kit (Pierce). Protein content was adjusted to 2 mg/mL and samples were subsequently diluted using 90% spotting buffer (PBS + 10% DMSO + 5% Glycerol) and 10% CLB1 (Zeptosen) to obtain four different protein concentrations corresponding to 100, 75, 50 and 25% (0.2 mg/mL, 0.15 mg/mL, 0.1 mg/mL and 0.05 mg/mL) of the primary spotting solution. The Nano-Plotter (GeSiM) impregnated the chips (Zeptosens) with drops (400 pL) of each dilution and these chips were blocked by nebulization with Blocking Buffer BB1 (Zeptosens) using the ZeptoFOG Blocking Station (Zeptosens).

For each of these four dilutions, duplicate spots were arrayed onto ZeptoMARK chips (Zeptosens) as single sample droplets of about 400 pL, using a Micro Pipetting System Nano-plotter™ (NP2.1, GeSiM, Großerkmannsdorf, Germany).

After spotting, the chips were dried for 1 h at 37°C and blocked in an ultrasonic nebulizer (ZeptoFOG, Zeptosens) with CeLyA Blocking Buffer (BB1, Zeptosens). Blocked chips were rinsed with water (Milli-Q quality), dried and stored at 4°C in the dark until further use. Antibody incubations were done in CeLyA Assay Buffer CAB1 based on BSA according to standard protocols (Zeptosens). The chips were assembled with chip fluidic structures in a ChipCARRIER (Zeptosens) and were incubated with primary antibodies (1:500 dilution in CAB1) overnight at room temperature. After rinsing the system with assay buffer, the chips were incubated with secondary fluorescence-labeled anti-species antibodies (Zenon Alexa Fluor 647, Molecular Probes) (1:500 dilution in CAB1) for 1h at room temperature. After rinsing the system with assay buffer to remove the excess secondary antibody, the fluorescence readout was performed with the ZeptoREADER instrument (Zeptosens).
at an extinction wavelength of 635 nm and an emission wavelength of 670 nm. The fluorescence signal was integrated over a period of 1–10 s, depending on the signal intensity. Array images were stored as 16-bit TIFF files and analyzed with the ZeptoView Pro software package (version 2.0, Zeptosens). Relative intensities were obtained by plotting net spot intensities against protein concentrations of the spotted samples determined by a Bradford assay as described above. Briefly, the eight datapoints for each sample were fitted using a weighted linear least squares fit. The relative intensity was then interpolated at the median protein concentration. The SD calculated from the fit is indicative for the linearity of the dilution series. Subsequently the data were renormalized to correct for small variations in protein content using β-actin as internal standard. Primary antibodies used were rabbit anti-human SPHK1 antibody (cat. nº: HPA022829, Sigma), mouse anti-human α-SMA (cat. nº: A5228, Sigma), rabbit anti-human Col Type I antibody (cat. nº: PA1-26204, Affinity Bioreagents, Golden, USA), mouse anti-human vimentin (cat. nº: V6389, Sigma).

**Western blot**

Western blot analysis was used to detect SPHK1, TGF-β1, α-SMA, vimentin, E-cadherin and p-Smad3 proteins in A549 cells. Cells were scraped from 25 cm² plates and lysed on ice with a lysis buffer consisting of 20mM Tris, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.9% NaCl, 0.1% Triton X-100, 1 mM dithiothreitol and 1 µg ml⁻¹ pepstatin A supplemented by a complete protease inhibitor cocktail. The Bio-Rad assay (Bio-Rad Laboratories Ltd., Herts, UK) was used to quantify the level of protein in each sample to ensure equal protein loading. Sodium dodecyl sulphate polyacrylamide gel electrophoresis was used to separate the proteins according to their molecular weight. Briefly, 20 µg of protein (denatured) mixed with
2x loading buffer (comprising 160mM Tris HCl (pH 6.8), 4% SDS, 20% glycerol, 1.4mM β-mercaptoethanol, 0.04% bromophenol blue) along with a molecular weight protein marker, Bio-Rad Kaleidoscope marker (Bio-Rad Laboratories), was loaded onto an acrylamide gel consisting of a 5% acrylamide stacking gel on top of a 12% acrylamide resolving gel and run through the gel by application of 100 V for 1 hour. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane using a wet blotting method. The membrane was blocked with 5% Marvel in PBS containing 0.1% Tween20 (PBS-T) and then probed with rabbit anti-human SPHK1 antibody (cat. nº: HPA022829, Sigma), goat anti-human TGF-β1 (1:1,000) antibody (monoclonal antibody; R&D Systems; catalogue no. AB-246-NA), human anti-mouse α-SMA (1:1000: cat. nº: A5228, Sigma), human anti-mouse E-cadherin (1:1000: cat. nº: CM1681, ECM BioSciences), human anti-mouse vimentin (1:1000: cat. nº: V6389, Sigma), p-Smad3 (1:1000: cat. nº: PS1023, Calbiochem) and a rabbit anti-human α-actin antibody (1:1000; Sigma, UK) or total Smad3 (1:1000: cat nº. 566414, Calbiochem) as house-keeping reference, followed by the corresponding peroxidase-conjugated secondary (1:10,000) antibody. The enhanced chemiluminescence method of protein detection using ECL-plus (GE Healthcare, Amersham Biosciences, UK) was used to detect labelled proteins. Quantification of protein expression was performed by densitometry relative to β-actin expression or total Smad3 expression using the software GeneSnap version 6.08.

**Immunohistochemistry**

For SPHK1 immunohistochemical analysis of human pulmonary tissue, specimens were fixed, embedded in paraffin, cut into sections (4–6 μm), and stained with haematoxylin, as reported previously. The sections were incubated with rabbit anti-
human SPHK1 antibody (1:100; Sigma) for 24 h at 4°C. Anti-rabbit secondary antibody (1:100; Vector Laboratories, Burlingame, CA, USA) conjugated with avidin-biotin complex/horseradish peroxidase was used for detection. Non-immune IgG isotype was used as a negative control.

**DCFDA fluorescence measurement of reactive oxygen species.**

A549 cells were treated with different S1P receptor antagonists at the same time that DCFDA. At the end of the incubation period (30 min) cells were stimulated with S1P or with the positive control H$_2$O$_2$ and intracellular fluorescence derived from DFC formation was monitored each 5 min. Results were expressed as DFC fluorescence in relative fluorescence units (RFU).

**Statistics**

All of the data analysis from human samples and clinical data were performed by non-parametric tests and described as median and interquartile range [IQR]. When the comparisons concerned only 2 groups, between-group differences were analyzed by the Mann Whitney test. Correlations between S1P levels and SPHK1 expression with the clinical features as well as correlations of $\alpha$-SMA, vimentin and col type I with SPHK1 lung tissue expression were analyzed using the Spearman correlation analysis. $p < 0.05$ was considered statistically significant.

For in vitro cell experiments performed in A549 cell line, results were expressed as mean (SE) of n experiments since Gaussian distribution for each data set was confirmed by histogram analyses and Kolmogorov–Smirnov test. In this case, statistical analysis
was carried out by parametric analysis of variance followed by appropriate post hoc tests including Bonferroni correction. Significance was accepted as $p < 0.05$.

**Discussion**

**Study limitations:**

In the present study, abundant S1P levels were found in the BAL fluid from patients with IPF, and high SPHK1 expression levels were identified in the lung tissues and alveolar macrophages. However, some important differences between our control and IPF groups need to be discussed. The proportion of smokers in the control group was higher than that in the IPF group. Although there is currently no evidence of an effect of cigarette smoke on S1P levels or SPHK expression, this represents a limitation of our work and warrants future research. Nevertheless, when smoker controls and smoker IPF patients were excluded in a post-hoc analysis, S1P serum and BAL levels as well as SPHK1 alveolar macrophage expression remained statistically higher in IPF patients discounting cigarette smoking as a confounding factor. Furthermore, we measured SPHK1 expression in alveolar macrophages because these are the main leukocytes recovered by BAL. In this sense, the high number of neutrophils in the BAL fluid of patients with IPF may be thought to have contributed to the elevated S1P levels observed in the BAL fluid. However, neutrophils have low amounts of S1P, negating this explanation.\(^\text{14}\) Another possible confusing factor is related to the higher proportion of patients with IPF treated with steroids. Currently, there is no evidence of an effect of steroids on serum and BAL levels of S1P. However, lower levels of S1P are expected in steroid-treated patients because S1P is considered to be a pro-inflammatory mediator in asthma,\(^\text{15}\) and steroids are immunosuppressors. In the present study, a post-hoc analysis
did not detect a statistical difference in the S1P level between untreated and steroid-treated patients.

As limitation of the in vitro data presented in the mechanistic experiments, it could be considered lacking in statistical power because the relatively small sample (3 to 4 independent experiments per condition). However, the homogeneous population of A549 cell line allow getting statistical significance with this number of experiments as we previously reported.3

Bibliography


